What is KeriCure?
KeriCure operates at the intersection of biotechnology and consumer wellness, specializing in natural, hypoallergenic first aid solutions. Founded by Dr. Kerriann Greenhalgh, the company addresses significant gaps in the over-the-counter wound care market by providing advanced alternatives for minor cuts, burns, and skin irritations. Their core product portfolio, which includes innovative liquid bandages and specialized sanitizers, is engineered to provide a protective barrier that promotes healing while minimizing the risk of infection.
The company distinguishes itself through a commitment to non-toxic, family-friendly formulations that cater to both human and veterinary needs. By maintaining a rigorous focus on skin health and biocompatibility, KeriCure has established a unique market position that appeals to both medical professionals seeking reliable clinical outcomes and families prioritizing safe, effective home care solutions.
How much funding has KeriCure raised?
KeriCure has raised a total of $800K across 1 funding round:
Unspecified
$800K
Unspecified (2012): $800K, investors not publicly disclosed
Key Investors in KeriCure
KeriCure
Undisclosed investor participating in the funding round.
What's next for KeriCure?
With the recent capital injection, KeriCure is poised to enter a phase of aggressive market penetration and operational scaling. The strategic roadmap likely involves enhancing manufacturing capabilities to meet rising demand and broadening the distribution network across major retail and clinical channels. Furthermore, the company is expected to invest in research and development to refine its existing liquid bandage technology and explore new applications for its hypoallergenic platform.
As KeriCure navigates this growth stage, the focus will remain on maintaining the integrity of its natural product formulations while scaling to meet the requirements of a larger, more diverse customer base. The firm is well-positioned to leverage its current momentum to capture a larger share of the wound care market, potentially setting new standards for safety and efficacy in the industry.
